Phase 1 clinical study of pembrolizumab biosimilar
Latest Information Update: 28 Mar 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 28 Mar 2023 New trial record
Latest Information Update: 28 Mar 2023